Mediplus, part of pharmaceutical group A&D Pharma, was ranked first among Romanian medicine exporters in 2012 and was followed by Europharm Brasov, controlled by GSK, and by Polisano, owned by businessman Ilie Vonica.
TMF Management and Picara Trading grabbed the fourth and fifth spots, respectively.
Vileus Med-Com, GlaxoSmithKline (GSK), SDS Inter Pharma, Farmexim, owned by businessman Ovidiu Buluc, and Infomed Fluids Bucharest, the local office of Italian firm ACS Dobfar, came next.
Vileus Med-Com Pitesti is entirely controlled by Gabriel Radu George and reported turnover of 169 million lei (EUR38 million) for 2012, almost triple on the year, and net profit of RON13.6 million.
SDS Inter Pharma was set up in 2010 and is owned by Salman Ummar (55.2%) and Aziz Imran (44.8%). The firm doubled its turnover to RON85 million last year and its net profit increased four times to RON2.3 million.
Mediplus registered turnover of over EUR700 million in 2012 and Polisano reported sales of EUR300 million. Farmexim came fourth with EUR285 million.
Romanian medical drug exports amounted to EUR882 million in 2012. According to data by the Association of Generic Drug Producers in Romania, Romanian medicine makers contributed EUR200 million to total exports, up 10% on the year. Europharm, Sandoz, Infomed Fluids, Actavis, Terapia and Antibiotice Iasi are among the Romanian drug producers which also export medicines.
Parallel exports are estimated at about 15%-20%, or EUR500 million, of the local pharmaceutical market.
According to the National Agency for Medicines and Medical Equipment (ANMDM), Germany, the UK, Sweden and Denmark were the main markets targeted by Romanian parallel exports.
According to INS data, Romania’s medicine exports to Germany amounted to over EUR250 million in 2012.
Pharmaceutical products worth EUR110 million were exported to the UK and the list also includes Russia (EUR88 million), France (EUR65 million), Denmark (EUR63 million), Ukraine (EUR44 million) Belgium (EUR34.4 million), Bulgaria (EUR29 million), the Netherlands (EUR22.3 million) and Poland (EUR18 million).
The Romanian pharmaceutical market amounted to EUR2.63 billion in 2012, up 3.1% on the year, according to market research company Cegedim Romania. Cegedim expects the local pharmaceutical market will rise 0.7% in 2013. (EUR1=RON4.45)